The global Antibody-Drug Conjugates (ADCs) market size is expected to reach USD 20.01 Billion at a steady revenue CAGR of 25.8% in 2028, according to latest analysis by Emergen Research. Increasing prevalence of cancer along with growing geriatric population is driving antibody-drug conjugates market revenue growth. Antibody drug conjugates are used to treat cancer and are safer than other types of cancer therapies.
Antibody-drug conjugates are highly targeted therapies that use biopharmaceutical drugs comprising monoclonal antibodies to target tumor cell specific antigens and extremely potent anti-cancer drugs linked through chemical linker. ADCs are considered a powerful and highly effective class of therapeutic agents used in oncology and hematology. ADC technology is also used outside of cancer-related indications.
Get a sample of the report @ https://www.emergenresearch.com/request-sample/754
ADCs are a targeted approach to deliver medicine and chemotherapy agents to cancer cells. Almost 8.2 million persons die each year due to cancer globally. Increasing prevalence of cancer in countries across the globe has created a rapid incline in demand for ADCs. Market players are collaborating to share resources and product knowledge to enhance effectiveness and efficiency of solutions and offerings and to develop even more advanced and effective drugs and therapies.
The report offers precise information about pricing, capacity, value, gross revenue, and profit of the market. The primary aim of the report is to offer in depth details about market size, revenue growth and overall market dynamics to readers, stakeholders, companies to strengthen their share in the global Antibody-Drug Conjugates Market. It also provides in depth information about key factors, restraints, limitations, challenges along with various market segmentations such as product type, application and regional bifurcation.
To know more about the report @ https://www.emergenresearch.com/industry-report/antibody-drug-conjugates-market
The report also discusses the key players involved in the market such as Oxford BioTherapeutics, Bayer AG, Immunomedics Inc., Concortis Biotherapeutics, F. Hoffman-La Roche Ltd., Pfizer Inc., ImmunoGen Inc., AbbVie Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited and others as well as new entrants in the market. It focuses on the recent mergers & acquisitions, joint ventures, collaborations, partnerships, licensing agreements, brand promotions, and product launches, among others. The report also provides details about the company overview, business expansion plans, product portfolio, manufacturing and production capacity, global market position, financial status, and consumer base.
Emergen Research has segmented the global Antibody-Drug Conjugates market on the basis of technology, application, end-use, and region:
Technology Outlook (Revenue, USD Billion; 2018–2028)
Cleavable Linker
Non-Cleavable Linker
Application Outlook (Revenue, USD Billion; 2018–2028)
Blood Cancer
Leukemia
Lymphoma
Brain Tumor
Ovarian Cancer
Breast Cancer
Lung Cancer
Others
End-use Outlook (Revenue, USD Billion; 2018–2028)
Hospitals
Research Institute
Clinics
Detailed Regional Analysis Covers:
North America
Canada
U.S.
Mexico
Europe
Germany
Italy
U.K.
Rest of EU
Asia Pacific
India
China
Japan
South Korea
Rest of APAC
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
U.A.E
Rest of MEA
Thank you for reading the research report. To get more information about the customized report and customization plan, kindly connect to us and we will provide you with the well-suited customized report.
About Us:
At Emergen Research, we believe in advancing with technology. We are growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
